PIK3CA
Despite promising Phase II data, ipatasertib failed to improve progression-free survival in TNBC patients with PIK3CA, AKT1, or PTEN tumor alterations.
Roche Nabs CE Mark for PIK3CA Test for Breast Cancer
The PCR-based test detects mutations in the PIK3CA gene that can cause cells to grow uncontrollably, possibly leading to cancer.
Advanced Breast Cancer Patients Benefit From Targeted, Conventional Therapy Combo, ESMO Studies Show
Premium
Two new studies show that patients with advanced HR-positive, HER2-negative breast cancer had higher survival when they received combination therapies.
Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy
A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and
Novartis' Piqray Approved in Canada for PIK3CA-Mutated Advanced Breast Cancer
The drugmaker said it is working with centers of excellence in Canada to set up companion diagnostic testing to identify patients with PIK3CA mutations.
Feb 3, 2020
Qiagen Obtains CE Mark for PIK3CA Mutation Assay
Oct 30, 2018
Precision Oncology Highlights From ESMO 2018
Jun 3, 2018